NIZORAL
LOE ApproachingNDAORALTABLETPriority Review
Approved
Jun 1981
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 16h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NIZORAL (ketoconazole) is an oral antifungal agent approved in 1981 for treating systemic fungal infections. The drug works by inhibiting fungal cell membrane synthesis through disruption of ergosterol production. It represents a foundational azole class therapy with broad-spectrum antifungal activity.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100), indicating potential contraction of brand team and shift toward defensive strategies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
NIZORAL offers limited career growth opportunity as a legacy oral antifungal approaching loss of exclusivity with zero linked job openings. Career relevance is primarily in defensive commercial strategies, generic transition management, or operational efficiency roles within Johnson & Johnson's mature product portfolio.
Brand Manager (defensive)Field Sales Representative
Worked on NIZORAL at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.